Selective TYK2 Inhibition, Prenatal Cell Diagnostics, and Biomarker-Guided Immunotherapy: Expanding Precision Medicine

Recent innovations showcase the power of selectivity in precision medicine. Brain-penetrant TYK2 inhibitors target autoimmune and neuroinflammatory disease, fetal cell diagnostics improve prenatal screening, and biomarker signatures refine checkpoint immunotherapy. Together, these advances highlight how molecular, cellular, and patient-level selectivity drives therapeutic precision across neurology, oncology, immunology, and reproductive health, reshaping diagnostics and treatment strategies from early development through complex disease.